Cargando…

Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy

AIMS/HYPOTHESIS: No established blood-based biomarker exists to monitor diabetic sensorimotor polyneuropathy (DSPN) and evaluate treatment response. The neurofilament light chain (NFL), a blood biomarker of neuroaxonal damage in several neurodegenerative diseases, represents a potential biomarker fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Maalmi, Haifa, Strom, Alexander, Petrera, Agnese, Hauck, Stefanie M., Strassburger, Klaus, Kuss, Oliver, Zaharia, Oana-Patricia, Bönhof, Gidon J., Rathmann, Wolfgang, Trenkamp, Sandra, Burkart, Volker, Szendroedi, Julia, Ziegler, Dan, Roden, Michael, Herder, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892145/
https://www.ncbi.nlm.nih.gov/pubmed/36472640
http://dx.doi.org/10.1007/s00125-022-05846-8
_version_ 1784881286630866944
author Maalmi, Haifa
Strom, Alexander
Petrera, Agnese
Hauck, Stefanie M.
Strassburger, Klaus
Kuss, Oliver
Zaharia, Oana-Patricia
Bönhof, Gidon J.
Rathmann, Wolfgang
Trenkamp, Sandra
Burkart, Volker
Szendroedi, Julia
Ziegler, Dan
Roden, Michael
Herder, Christian
author_facet Maalmi, Haifa
Strom, Alexander
Petrera, Agnese
Hauck, Stefanie M.
Strassburger, Klaus
Kuss, Oliver
Zaharia, Oana-Patricia
Bönhof, Gidon J.
Rathmann, Wolfgang
Trenkamp, Sandra
Burkart, Volker
Szendroedi, Julia
Ziegler, Dan
Roden, Michael
Herder, Christian
author_sort Maalmi, Haifa
collection PubMed
description AIMS/HYPOTHESIS: No established blood-based biomarker exists to monitor diabetic sensorimotor polyneuropathy (DSPN) and evaluate treatment response. The neurofilament light chain (NFL), a blood biomarker of neuroaxonal damage in several neurodegenerative diseases, represents a potential biomarker for DSPN. We hypothesised that higher serum NFL levels are associated with prevalent DSPN and nerve dysfunction in individuals recently diagnosed with diabetes. METHODS: This cross-sectional study included 423 adults with type 1 and type 2 diabetes and known diabetes duration of less than 1 year from the prospective observational German Diabetes Study cohort. NFL was measured in serum samples of fasting participants in a multiplex approach using proximity extension assay technology. DSPN was assessed by neurological examination, nerve conduction studies and quantitative sensory testing. Associations of serum NFL with DSPN (defined according to the Toronto Consensus criteria) were estimated using Poisson regression, while multivariable linear and quantile regression models were used to assess associations with nerve function measures. In exploratory analyses, other biomarkers in the multiplex panel were also analysed similarly to NFL. RESULTS: DSPN was found in 16% of the study sample. Serum NFL levels increased with age. After adjustment for age, sex, waist circumference, height, HbA(1c), known diabetes duration, diabetes type, cholesterol, eGFR, hypertension, CVD, use of lipid-lowering drugs and use of non-steroidal anti-inflammatory drugs, higher serum NFL levels were associated with DSPN (RR [95% CI] per 1-normalised protein expression increase, 1.92 [1.50, 2.45], p<0.0001), slower motor (all p<0.0001) and sensory (all p≤0.03) nerve conduction velocities, lower sural sensory nerve action potential (p=0.0004) and higher thermal detection threshold to warm stimuli (p=0.023 and p=0.004 for hand and foot, respectively). There was no evidence for associations between other neurological biomarkers and DSPN or nerve function measures. CONCLUSIONS/INTERPRETATION: Our findings in individuals recently diagnosed with diabetes provide new evidence associating higher serum NFL levels with DSPN and peripheral nerve dysfunction. The present study advocates NFL as a potential biomarker for DSPN. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00125-022-05846-8) contains peer-reviewed but unedited supplementary material..
format Online
Article
Text
id pubmed-9892145
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-98921452023-02-03 Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy Maalmi, Haifa Strom, Alexander Petrera, Agnese Hauck, Stefanie M. Strassburger, Klaus Kuss, Oliver Zaharia, Oana-Patricia Bönhof, Gidon J. Rathmann, Wolfgang Trenkamp, Sandra Burkart, Volker Szendroedi, Julia Ziegler, Dan Roden, Michael Herder, Christian Diabetologia Article AIMS/HYPOTHESIS: No established blood-based biomarker exists to monitor diabetic sensorimotor polyneuropathy (DSPN) and evaluate treatment response. The neurofilament light chain (NFL), a blood biomarker of neuroaxonal damage in several neurodegenerative diseases, represents a potential biomarker for DSPN. We hypothesised that higher serum NFL levels are associated with prevalent DSPN and nerve dysfunction in individuals recently diagnosed with diabetes. METHODS: This cross-sectional study included 423 adults with type 1 and type 2 diabetes and known diabetes duration of less than 1 year from the prospective observational German Diabetes Study cohort. NFL was measured in serum samples of fasting participants in a multiplex approach using proximity extension assay technology. DSPN was assessed by neurological examination, nerve conduction studies and quantitative sensory testing. Associations of serum NFL with DSPN (defined according to the Toronto Consensus criteria) were estimated using Poisson regression, while multivariable linear and quantile regression models were used to assess associations with nerve function measures. In exploratory analyses, other biomarkers in the multiplex panel were also analysed similarly to NFL. RESULTS: DSPN was found in 16% of the study sample. Serum NFL levels increased with age. After adjustment for age, sex, waist circumference, height, HbA(1c), known diabetes duration, diabetes type, cholesterol, eGFR, hypertension, CVD, use of lipid-lowering drugs and use of non-steroidal anti-inflammatory drugs, higher serum NFL levels were associated with DSPN (RR [95% CI] per 1-normalised protein expression increase, 1.92 [1.50, 2.45], p<0.0001), slower motor (all p<0.0001) and sensory (all p≤0.03) nerve conduction velocities, lower sural sensory nerve action potential (p=0.0004) and higher thermal detection threshold to warm stimuli (p=0.023 and p=0.004 for hand and foot, respectively). There was no evidence for associations between other neurological biomarkers and DSPN or nerve function measures. CONCLUSIONS/INTERPRETATION: Our findings in individuals recently diagnosed with diabetes provide new evidence associating higher serum NFL levels with DSPN and peripheral nerve dysfunction. The present study advocates NFL as a potential biomarker for DSPN. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00125-022-05846-8) contains peer-reviewed but unedited supplementary material.. Springer Berlin Heidelberg 2022-12-06 2023 /pmc/articles/PMC9892145/ /pubmed/36472640 http://dx.doi.org/10.1007/s00125-022-05846-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Maalmi, Haifa
Strom, Alexander
Petrera, Agnese
Hauck, Stefanie M.
Strassburger, Klaus
Kuss, Oliver
Zaharia, Oana-Patricia
Bönhof, Gidon J.
Rathmann, Wolfgang
Trenkamp, Sandra
Burkart, Volker
Szendroedi, Julia
Ziegler, Dan
Roden, Michael
Herder, Christian
Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy
title Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy
title_full Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy
title_fullStr Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy
title_full_unstemmed Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy
title_short Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy
title_sort serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892145/
https://www.ncbi.nlm.nih.gov/pubmed/36472640
http://dx.doi.org/10.1007/s00125-022-05846-8
work_keys_str_mv AT maalmihaifa serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT stromalexander serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT petreraagnese serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT hauckstefaniem serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT strassburgerklaus serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT kussoliver serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT zahariaoanapatricia serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT bonhofgidonj serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT rathmannwolfgang serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT trenkampsandra serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT burkartvolker serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT szendroedijulia serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT zieglerdan serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT rodenmichael serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT herderchristian serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy
AT serumneurofilamentlightchainanovelbiomarkerforearlydiabeticsensorimotorpolyneuropathy